SCHEMBL25260705

SCHEMBL25260705

CC(=O)C(C)(C)c1c(F)cccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 4/20 0.43
▸ CES1 P23141 4/20 0.43
▸ BCHE P06276 1/20 0.39
▸ ALB P02768 1/20 0.36
▸ ERN1 O75460 1/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RIPK1 Q13546 2/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TTR P02766 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12488048 0.88 THRB (0.41) CES2CES1BCHEALBERN1
SCHEMBL15501814 0.87 GAA (0.42) CES2CES1PDK1PDK2PDK3
SCHEMBL12585680 0.83 CES2 (0.43) CES2CES1BCHEALBPDK1
SCHEMBL3861716 0.81 MAPT (0.50) CES2CES1BCHEKMT2ATTR
SCHEMBL19750835 0.81 CES2 (0.43) CES2CES1BCHEKMT2ARIPK1
SCHEMBL25260011 0.79 CES2 (0.40) CES2CES1BCHEALBPDK1
SCHEMBL25848122 0.78 CES2 (0.33) CES2CES1BCHEERN1ALDH1A1
SCHEMBL25304324 0.78 KCNN4 (0.41) CES2CES1PDK1PDK2PDK3
SCHEMBL25460824 0.78 GAA (0.44) CES2CES1BCHEALBPDK1
SCHEMBL12841736 0.77 KCNN4 (0.46) CES2CES1PDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163039-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2025-05-22 — — US disclosed
EP-4452964-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER Boehringer Ingelheim International GmbH (DE) 2024-10-30 — — EP disclosed
CN-118339153-A Heteroaromatic compounds for the treatment of cancer 勃林格殷格翰国际有限公司 2024-07-12 — — CN disclosed
WO-2023117681-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-06-29 — — WO disclosed
WO-2023117681-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163039-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER NRAS, KRAS, RB1 CES2 4210/4885CES1 3301/4885BCHE 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback